Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants.

Ma JK, Drossard J, Lewis D, Altmann F, Boyle J, Christou P, Cole T, Dale P, van Dolleweerd CJ, Isitt V, Katinger D, Lobedan M, Mertens H, Paul MJ, Rademacher T, Sack M, Hundleby PA, Stiegler G, Stoger E, Twyman RM, Vcelar B, Fischer R.

Plant Biotechnol J. 2015 Oct;13(8):1106-20. doi: 10.1111/pbi.12416. Epub 2015 Jul 3.

2.

Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.

Blackwell K, Semiglazov V, Krasnozhon D, Davidenko I, Nelyubina L, Nakov R, Stiegler G, Singh P, Schwebig A, Kramer S, Harbeck N.

Ann Oncol. 2015 Sep;26(9):1948-53. doi: 10.1093/annonc/mdv281. Epub 2015 Jun 28.

3.

Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide.

Rodrigueza WV, Woolliscroft MJ, Ebrahim AS, Forgey R, McGovren PJ, Endert G, Wagner A, Holewa D, Aboukameel A, Gill RD, Bisgaier CL, Messmann RA, Whitehead CE, Izbicka E, Streeper R, Wick MC, Stiegler G, Stein CA, Monsma D, Webb C, Sooch MP, Panzner S, Mohammad R, Goodwin NC, Al-Katib A.

Cancer Chemother Pharmacol. 2014 Jul;74(1):151-66. doi: 10.1007/s00280-014-2476-y. Epub 2014 May 16.

4.

Preparation of granulocyte concentrates by apheresis.

Leitner G, Panzer S, Reesink HW, Stiegler G, Fischer-Nielsen A, Dickmeiss E, Einsele H, Reinhardt P, Schrezenmeier H, Wiesneth M, Coluccia P, Nygell UA, Halter J, Sigle J, Gratwohl A, Buser AS, Ozturk G, Anak S.

Vox Sang. 2010 May;98(4):567-75. doi: 10.1111/j.1423-0410.2010.01315.x. No abstract available.

PMID:
20529074
5.

Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody.

Joseph A, Zheng JH, Chen K, Dutta M, Chen C, Stiegler G, Kunert R, Follenzi A, Goldstein H.

J Virol. 2010 Jul;84(13):6645-53. doi: 10.1128/JVI.02339-09. Epub 2010 Apr 21.

6.

Characterization of a trimeric MPER containing HIV-1 gp41 antigen.

Hinz A, Schoehn G, Quendler H, Hulsik DL, Stiegler G, Katinger H, Seaman MS, Montefiori D, Weissenhorn W.

Virology. 2009 Aug 1;390(2):221-7. doi: 10.1016/j.virol.2009.05.015. Epub 2009 Jun 18.

7.

P-selectin mRNA is maintained in platelet concentrates stored at 4 degrees C.

Stiegler G, Fischer G, Ramanathan G, Bencur P, Weigel G, Mannhalter C.

Transfusion. 2009 May;49(5):921-7. doi: 10.1111/j.1537-2995.2008.02073.x. Epub 2009 Jan 21.

8.

Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure.

Strasser R, Stadlmann J, Schähs M, Stiegler G, Quendler H, Mach L, Glössl J, Weterings K, Pabst M, Steinkellner H.

Plant Biotechnol J. 2008 May;6(4):392-402. doi: 10.1111/j.1467-7652.2008.00330.x. Epub 2008 Mar 13.

9.

Cost-effective production of a vaginal protein microbicide to prevent HIV transmission.

Ramessar K, Rademacher T, Sack M, Stadlmann J, Platis D, Stiegler G, Labrou N, Altmann F, Ma J, Stöger E, Capell T, Christou P.

Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3727-32. doi: 10.1073/pnas.0708841104. Epub 2008 Mar 3.

10.

Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked.

Huber M, von Wyl V, Ammann CG, Kuster H, Stiegler G, Katinger H, Weber R, Fischer M, Stoiber H, Günthard HF, Trkola A.

J Virol. 2008 Apr;82(8):3834-42. doi: 10.1128/JVI.02569-07. Epub 2008 Jan 30.

11.

Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data.

Vcelar B, Stiegler G, Wolf HM, Muntean W, Leschnik B, Mehandru S, Markowitz M, Armbruster C, Kunert R, Eibl MM, Katinger H.

AIDS. 2007 Oct 18;21(16):2161-70.

PMID:
18090042
12.

In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers.

Trkola A, Kuster H, Rusert P, von Wyl V, Leemann C, Weber R, Stiegler G, Katinger H, Joos B, Günthard HF.

J Virol. 2008 Feb;82(3):1591-9. Epub 2007 Nov 21.

13.

One step membrane incorporation of viral antigens as a vaccine candidate against HIV.

Wagner A, Stiegler G, Vorauer-Uhl K, Katinger H, Quendler H, Hinz A, Weissenhorn W.

J Liposome Res. 2007;17(3-4):139-54.

PMID:
18027234
14.

Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV-1 and contains predominantly single-GlcNAc N-glycans.

Rademacher T, Sack M, Arcalis E, Stadlmann J, Balzer S, Altmann F, Quendler H, Stiegler G, Kunert R, Fischer R, Stoger E.

Plant Biotechnol J. 2008 Feb;6(2):189-201. Epub 2007 Nov 3.

15.

Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection.

Mehandru S, Vcelar B, Wrin T, Stiegler G, Joos B, Mohri H, Boden D, Galovich J, Tenner-Racz K, Racz P, Carrington M, Petropoulos C, Katinger H, Markowitz M.

J Virol. 2007 Oct;81(20):11016-31. Epub 2007 Aug 8.

16.

In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

Manrique A, Rusert P, Joos B, Fischer M, Kuster H, Leemann C, Niederöst B, Weber R, Stiegler G, Katinger H, Günthard HF, Trkola A.

J Virol. 2007 Aug;81(16):8793-808. Epub 2007 Jun 13.

17.

Functional analysis of the broadly neutralizing human anti-HIV-1 antibody 2F5 produced in transgenic BY-2 suspension cultures.

Sack M, Paetz A, Kunert R, Bomble M, Hesse F, Stiegler G, Fischer R, Katinger H, Stoeger E, Rademacher T.

FASEB J. 2007 Jun;21(8):1655-64. Epub 2007 Feb 27.

PMID:
17327362
18.

Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion.

Dimitrov AS, Jacobs A, Finnegan CM, Stiegler G, Katinger H, Blumenthal R.

Biochemistry. 2007 Feb 6;46(5):1398-401.

PMID:
17260969
19.

Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning.

Zhang MY, Choudhry V, Sidorov IA, Tenev V, Vu BK, Choudhary A, Lu H, Stiegler GM, Katinger HW, Jiang S, Broder CC, Dimitrov DS.

J Immunol Methods. 2006 Dec 20;317(1-2):21-30. Epub 2006 Oct 16.

20.

Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques.

Ferrantelli F, Buckley KA, Rasmussen RA, Chalmers A, Wang T, Li PL, Williams AL, Hofmann-Lehmann R, Montefiori DC, Cavacini LA, Katinger H, Stiegler G, Anderson DC, McClure HM, Ruprecht RM.

Virology. 2007 Feb 5;358(1):69-78. Epub 2006 Sep 25.

21.

GMP production of liposomes--a new industrial approach.

Wagner A, Platzgummer M, Kreismayr G, Quendler H, Stiegler G, Ferko B, Vecera G, Vorauer-Uhl K, Katinger H.

J Liposome Res. 2006;16(3):311-9.

PMID:
16952884
22.

Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).

Joos B, Trkola A, Kuster H, Aceto L, Fischer M, Stiegler G, Armbruster C, Vcelar B, Katinger H, Günthard HF.

Antimicrob Agents Chemother. 2006 May;50(5):1773-9.

23.

HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies.

Nakowitsch S, Quendler H, Fekete H, Kunert R, Katinger H, Stiegler G.

AIDS. 2005 Nov 18;19(17):1957-66.

PMID:
16260901
24.

Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment.

Kittel C, Ferko B, Kurz M, Voglauer R, Sereinig S, Romanova J, Stiegler G, Katinger H, Egorov A.

J Virol. 2005 Aug;79(16):10672-7.

25.

Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.

Rusert P, Kuster H, Joos B, Misselwitz B, Gujer C, Leemann C, Fischer M, Stiegler G, Katinger H, Olson WC, Weber R, Aceto L, Günthard HF, Trkola A.

J Virol. 2005 Jul;79(13):8454-69.

26.

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.

Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, Weber R, Stiegler G, Vcelar B, Katinger H, Aceto L, Günthard HF.

Nat Med. 2005 Jun;11(6):615-22. Epub 2005 May 8.

PMID:
15880120
27.

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, Robinson J, Scearce RM, Plonk K, Staats HF, Ortel TL, Liao HX, Alam SM.

Science. 2005 Jun 24;308(5730):1906-8. Epub 2005 Apr 28.

28.

The influence of human platelet antigen match on the success of allogeneic peripheral blood progenitor cell transplantation following a reduced-intensity conditioning regimen.

Leitner GC, Stiegler G, Kalhs P, Greinix HT, Rabitsch W, Sillaber C, Hoecker P, Panzer S.

Transfusion. 2005 Feb;45(2):195-201.

PMID:
15660827
29.
30.

Trimeric membrane-anchored gp41 inhibits HIV membrane fusion.

Lenz O, Dittmar MT, Wagner A, Ferko B, Vorauer-Uhl K, Stiegler G, Weissenhorn W.

J Biol Chem. 2005 Feb 11;280(6):4095-101. Epub 2004 Dec 1.

31.

Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10.

Mehandru S, Wrin T, Galovich J, Stiegler G, Vcelar B, Hurley A, Hogan C, Vasan S, Katinger H, Petropoulos CJ, Markowitz M.

J Virol. 2004 Dec;78(24):14039-42.

32.

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.

Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR.

J Virol. 2004 Dec;78(23):13232-52.

33.

Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12.

Armbruster C, Stiegler GM, Vcelar BA, Jäger W, Köller U, Jilch R, Ammann CG, Pruenster M, Stoiber H, Katinger HW.

J Antimicrob Chemother. 2004 Nov;54(5):915-20. Epub 2004 Sep 29.

PMID:
15456731
34.
35.

Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies.

Ferrantelli F, Rasmussen RA, Buckley KA, Li PL, Wang T, Montefiori DC, Katinger H, Stiegler G, Anderson DC, McClure HM, Ruprecht RM.

J Infect Dis. 2004 Jun 15;189(12):2167-73. Epub 2004 May 26.

PMID:
15181562
36.

Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination.

Zhang L, Ribeiro RM, Mascola JR, Lewis MG, Stiegler G, Katinger H, Perelson AS, Davenport MP.

J Virol. 2004 May;78(10):5520-2.

37.

Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine.

Ferrantelli F, Kitabwalla M, Rasmussen RA, Cao C, Chou TC, Katinger H, Stiegler G, Cavacini LA, Bai Y, Cotropia J, Ugen KE, Ruprecht RM.

J Infect Dis. 2004 Jan 1;189(1):71-4. Epub 2003 Dec 31.

PMID:
14702155
38.

Influence of human platelet antigen match on the success of stem cell transplantation after myeloablative conditioning.

Leitner GC, Tanzmann A, Stiegler G, Kalhs P, Greinix HT, Hoecker P, Panzer S.

Bone Marrow Transplant. 2003 Oct;32(8):821-4.

PMID:
14520428
39.

Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.

Mascola JR, Lewis MG, VanCott TC, Stiegler G, Katinger H, Seaman M, Beaudry K, Barouch DH, Korioth-Schmitz B, Krivulka G, Sambor A, Welcher B, Douek DC, Montefiori DC, Shiver JW, Poignard P, Burton DR, Letvin NL.

J Virol. 2003 Oct;77(19):10348-56.

40.

Ice from an ice machine is a potential source of bacterial contamination for HPC products -- implications for cell-processing facilities.

Stiegler G, Gerhartl K, Jurko S, Leitner G, Höcker P, Dettke M.

Cytotherapy. 2003;5(4):346-7. No abstract available.

PMID:
12944241
41.

Mechanism(s) promoting HIV-1 infection of primary unstimulated T lymphocytes in autologous B cell/T cell co-cultures.

Döpper S, Wilflingseder D, Prodinger WM, Stiegler G, Speth C, Dierich MP, Stoiber H.

Eur J Immunol. 2003 Aug;33(8):2098-107.

42.

Quality of packed red blood cells and platelet concentrates collected by multicomponent collection using the MCS plus device.

Leitner GC, Jilma-Stohlawetz P, Stiegler G, Weigel G, Horvath M, Tanzmann A, Höcker P, Fischer MB.

J Clin Apher. 2003;18(1):21-5.

PMID:
12717789
43.

Idiopathic autoimmune thrombocytopenia: evidence for redistribution of platelet antibodies into the circulation after immunoadsorption treatment.

Leitner GC, Stiegler G, Horvath M, Hoecker P, Sagaster P, Panzer S.

Am J Hematol. 2003 May;73(1):44-7.

44.

Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection.

Stiegler G, Katinger H.

J Antimicrob Chemother. 2003 Apr;51(4):757-9. Epub 2003 Mar 13. Review. No abstract available.

PMID:
12654737
45.

Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B.

Kitabwalla M, Ferrantelli F, Wang T, Chalmers A, Katinger H, Stiegler G, Cavacini LA, Chou TC, Ruprecht RM.

AIDS Res Hum Retroviruses. 2003 Feb;19(2):125-31.

PMID:
12639248
47.

Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques.

Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, Wang T, Xu W, Li PL, Montefiori DC, Cavacini LA, Katinger H, Stiegler G, Anderson DC, McClure HM, Ruprecht RM.

AIDS. 2003 Feb 14;17(3):301-9.

PMID:
12556683
48.

Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation.

Stiegler G, Armbruster C, Vcelar B, Stoiber H, Kunert R, Michael NL, Jagodzinski LL, Ammann C, Jäger W, Jacobson J, Vetter N, Katinger H.

AIDS. 2002 Oct 18;16(15):2019-25.

PMID:
12370500
49.

Postnatal pre- and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge.

Hofmann-Lehmann R, Vlasak J, Rasmussen RA, Jiang S, Li PL, Baba TW, Montefiori DC, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Katinger H, Stiegler G, Cavacini LA, Posner MR, Ruprecht RM.

J Med Primatol. 2002 Jun;31(3):109-19.

PMID:
12190851
50.

Post-transfusion purpura without detectable antibodies: their adsorption from the plasma by multiple incompatible platelet transfusions.

Leitner GC, Stiegler G, Hetz H, Horvath M, Höcker P, Panzer S.

Br J Haematol. 2002 Jun;117(4):994-5. No abstract available.

PMID:
12060144

Supplemental Content

Loading ...
Support Center